Published in final edited form as:

J Med Chem. 2018 February 22; 61(4): 1595–1608. doi:10.1021/acs.jmedchem.7b01710.

New Steroidal 4-Aminoquinolines Antagonize Botulinum Neurotoxin Serotype A in Mouse Embryonic Stem Cell Derived Motor Neurons in Post-intoxication Model

Jelena Konstantinovi [¶], Erkan Kiriş[‡], Krishna P. Kota[†], Johanny Kugelman Tonos[†], Milica Videnovi [#], Lisa H. Cazares[†], Nataša Terzi Jovanovi [▽], Tatjana Ž. Verbi [¶], Boban Andjelkovi [¶], Allen J. Duplantier[†], Sina Bavari^{*‡}, and Bogdan A. Šolaja^{*¶§}

[¶]University of Belgrade, Faculty of Chemistry, Studentski trg 16, P.O. Box 51, 11158, Belgrade, Serbia

[‡]Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States

[†]Molecular and Translational Sciences Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Frederick, Maryland 21702, United States

[#]Faculty of Chemistry Innovative Centre, Studentski trg 12 16, 11158 Belgrade, Serbia

[▽]University of Belgrade, Institute of Chemistry, Technology, and Metallurgy, Njegoševa 12, 11000 Belgrade, Serbia

[‡]United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Frederick, Maryland 21702, United States

[§]Serbian Academy of Sciences and Arts, Knez Mihailova 35, 11158 Belgrade, Serbia

Abstract

***Corresponding Author:** For B.Š.: phone, +381-11-263-86-06; fax, +381-11-263-60-61; bsolaja@chem.bg.ac.rs; bogdan.solaja@sanu.ac.rs.; For S.B.: phone, +1-301-619-4261; Fax: +1-301-619-2348; sina.bavari.civ@mail.mil.

ORCID

Bogdan A. Šolaja: <https://orcid.org/0000-0002-9975-2725>

Author Contributions

B.Š. and S.B. designed the research. Part of the projected dissertation of J.K., University of Belgrade. The manuscript was written by J.K. with contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

Opinions, interpretations, conclusions, and recommendations stated within the article are those of the authors and are not necessarily endorsed by the U.S. Army nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The authors declare no competing financial interest.

Supporting Information.

The following files are available free of charge.

Supporting information – I, PDF

Inhibitory activities against BoNT/A LC and holotoxin in proteolytic and cell-based assay for all tested compounds; fluorescence and UV-Vis spectra for determination of **16** binding to HSA and AGP; ligand interaction diagrams, docking scores and docking-in vitro inhibitory activity correlations; spectral and analytical data for all synthesized compounds; detailed procedures for the determination of the HPLC purity.

Supporting information – II, PDF

NMR spectra and HPLC purity spectra of all tested compounds.

Molecular Formula Strings, CSV

The synthesis and inhibitory potencies against botulinum neurotoxin serotype A light chain (BoNT/A LC) using in vitro HPLC based enzymatic assay for various steroidal, benzothiophene, thiophene and adamantane 4 aminoquinoline derivatives is described. In addition, the compounds were evaluated for the activity against BoNT/A holotoxin in mouse embryonic stem cell derived motor neurons. Steroidal derivative **16** showed remarkable protection (up to 89% of uncleaved SNAP 25) even when administered 30 minutes post intoxication. This appears to be the first example of LC inhibitors antagonizing BoNT intoxication in mouse embryonic stem cell derived motor neurons (mES MNs) in a post-exposure model. Oral administration of **16** was well tolerated in the mouse up to 600 mg/kg, qd. Although adequate unbound drug levels were not achieved at this dose, the favorable in vitro ADMET results strongly support further work in this series.

TOC image

INTRODUCTION

Botulinum neurotoxins (BoNTs) are proteins produced by the Gram positive anaerobic bacterium *Clostridium botulinum*. They are amongst the most potent toxins known and are causative agents of botulism, a serious and life threatening illness in humans and animals.¹ There are at least seven distinct serotypes (A-G), however, three of them (A, B and E) are considered the most noxious in humans.^{2,3} The majority of efforts have been focused on identification of BoNT/A inhibitors with intracellular activity, because antibody based treatments were found successful only before toxin enters a neuron.⁴ Recent reviews have covered the in vitro in - vivo gap in this field,⁴ focusing on small molecule non-peptide inhibitors (SMNPI), potential drug targets and the MOA of these SMNPIs.^{5,6} Very recently, several approaches using SMNPIs have been explored by targeting the host intoxication pathways not by directly inhibiting the toxins' proteolytic activity but focusing on Src family kinase signaling,⁷ thioredoxin reductase system^{8,9} and by the development of phosphatase inhibitors that would have an impact on BoNT intoxication in motor neurons.¹⁰ The alternative approach was also developed, the inhibitors that interact with BoNT/A LC; among them the hydroxamates¹¹ and aminoquinolines showed high inhibitory activities against BoNT/A LC in cell free assays.^{12–16} Diverse cell-based assays have been used as more relevant methods for evaluation of new drugs capable of protecting SNAP-25 from BoNT/A LC cleavage.^{17–20} More importantly, these methods simulate all key steps in intoxication process, starting from holotoxin binding to the cell surface to cleavage of the SNARE proteins.^{21,17} Since there is a continuous need for discovering new therapeutics for treatment of BoNT/A intoxication, this method is considered to be a very helpful tool for narrowing the spectrum of compounds for testing in animal models. Ex vivo assays, such as the mouse hemidiaphragm assay for BoNT/A induced muscle paralysis are also widely used for evaluating new drug candidates (e.g. quinolin 8 ol inhibitors²² and EGA²³). Despite several attempts,^{23–27} there is still no inhibitor that is significantly effective in an animal

model of intoxication, especially when administered post toxin injection. Recently published complexes of Cu(II) with dithiocarbamate and bis(thiosemicarbazone) are also only capable of extending time to death of BoNT/A intoxicated mice.²⁸ Similarly, newly published mercaptoacetamide inhibitor **ABS 252** proved to be effective in extending survival of BoNT intoxicated mice.²⁹ Presently, the only SMNPI with anti-BoNT/A activity in the mouse model is **Dynngo-4a** which administered 3 h post-intoxication provides 30% mice survival for 24 h.³⁰ For the treatment of BoNT intoxication, it is necessary for inhibitors to reach the neuromuscular junction and enter the neuronal cell. Thus, adequate drug exposure at the target tissue is key, and in vitro ADMET parameters such as solubility, microsomal stability, permeability and plasma protein binding can be used as an effective means to down select active compounds capable of providing acceptable PK properties.

We designed our new BoNT/A LC inhibitors according to structure-based docking simulations.¹⁶ Since docking simulations indicated that besides steroids the benzothiophene derivatives of aminoquinoline also fit into the binding cleft of BoNT/A LC (keeping the main interactions with amino acid residues within the active site, c.f. Supporting information), we decided to investigate the contribution of other carriers to the inhibitory activity (Chart 1).

Here, we report on the synthesis, pharmacokinetic analysis and detailed evaluation of new steroidal, benzothiophene, thiophene and adamantane 4 aminoquinoline inhibitors of BoNT/A LC and their respective inhibitory potencies against BoNT/A holotoxin in mouse embryonic stem cell derived motor neurons (mES MNs).

CHEMISTRY

Continuing our search for efficient BoNT/A inhibitors, we report on new steroidal derivatives with improved inhibitory activities against BoNT/A LC. Here, we focus on steroidal derivatives with a basic amino group at C(3), varying the linker connecting the steroidal and aminoquinoline components. Also, we examined three other classes of aminoquinoline derivatives with benzothiophene, thiophene and adamantane carriers for their inhibitory activities against BoNT/A LC. All steroidal, benzothiophene, thiophene and adamantane derivatives were synthesized according to our established procedures (Schemes 1 and 3).^{16,31,32} All tested inhibitors were fully characterized and their purities were >95% (as determined by HPLC, Supporting Information).

Based on our earlier findings,¹⁶ the newly synthesized steroidal inhibitors were chosen for essential SAR studies within the series. To that purpose, we varied the substitution at carbon atoms next to nitrogens, at N C(24) and substitution at quinoline C(7) position. Steroidal derivatives were obtained by reductive amination starting from C(24) alcohol derivative **3**.¹⁶ After removal of protecting group, compounds **14**, **16**, **17** and **19–23** were obtained in moderate to excellent yield (48–97%). In addition, subjecting the Boc-protected derivatives to reductive amination with 37% formaldehyde and NaBH₃CN followed by removal of the protecting group afforded *N*-methylated derivatives **15** and **18** in acceptable yields (56–60%). Due to the presence of the methyl group at N-C(α), compounds **17–21** were obtained as mixture of diastereomers and were tested as such (vide infra). According to our docking

model only C(7) (and not (C12)) acetoxy group is directing structural element featuring the Zn^{2+} chelation so favorably contributing to inhibitor's diving into catalytic cleft (Fig. S11–S13).¹⁶ The inhibitor **24** (68%) was obtained by hydrolysis of acetoxy groups in **16** with potassium hydroxide in methanol (Scheme 1).

Steroidal derivative **30** with the amide functional group next to quinoline was prepared in order to explore the effect of changes in $\text{p}K_a$ and conformation on inhibitory activity. *N*-Boc protected derivative **29** was obtained in 43% yield by reductive amination of steroidal C(24) aldehyde and amine **28** (prepared in few steps starting from 4,7-dichloroquinoline). It has been noticed that amine **28** decomposes to **25** and pyrrolidine 2-one, therefore, it was used in next step without detailed characterization. The final compound **30** was obtained in good yield (80%) after removal of the Boc protecting group (Scheme 2).

Synthesis of novel benzothiophene and thiophene derivatives is presented in Scheme 3. Benzothiophene and thiophene derivatives **33**, **34**, **42–45** and **50** were obtained by reductive amination from corresponding aldehydes (**31**, **39–41** and **49**) in moderate yield (12–77%). Compound **47** was obtained from **45** after removal of TMS-group in moderate yield. Benzothiophene and thiophene *N*-methyl tertiary amino derivatives, **37**, **38** and **48** were synthesized by reaction of formaldehyde with secondary amines **35**, **36** and **46** respectively, reported in our previous work.^{31,33}

Syntheses of novel adamantane derivatives are presented in Scheme 4. Adamantane derivatives with tertiary nitrogen **56–65**, **68** and **69** were obtained using the same procedures as mentioned above in moderate to excellent yield (55–93%) after coupling of prepared amines (**51–55**, **AQ11**, **AQ7**, **AQ8**)^{13,32,34} to corresponding aldehydes. Key reaction for synthesis of adamantane derivatives **77–82** was the Pd-mediated Buchwald coupling of previously prepared amines (**70–75**)³² to 4-chloroquinoline in moderate to excellent yield (44–91%). Compounds **84** and **85** were obtained in high yield by methylation of compounds **78** and **83**, respectively.

RESULTS

Recently, we discovered steroidal *bis*-aminoquinoline (*bis*-ACQ) inhibitors with 90–97% BoNT/A LC inhibition and K_i values within the range 0.103–0.389 μM (such as **1**, Chart 1).¹⁶ However, several comments regarding our hit compounds should be considered. Simplifying the original structure should be desired since the synthesis of *bis*-ACQ derivatives and purification thereof is rather demanding task. In addition, the compounds with $\text{MW} > 900$, although of natural product origin, are not commonly considered drug-like and could have difficulties in reaching the target as well. Therefore, we have chosen the compound **2** (Chart 1),¹⁶ with $\text{IC}_{50} = 0.81 \mu\text{M}$ and $K_i = 3.22 \mu\text{M}$ in HPLC-based assay and 77% of SNAP-25 protection at 30 μM in pre-intoxication scenario in embryonic chicken spinal primary neurons as very promising starting point for further improvement of the steroidal inhibitors.

Evaluation of Inhibitory Activity Against BoNT/A LC

Inhibitory activities against BoNT/A LC in proteolytic and against holotoxin in cell-based assay are presented in Table 1. In vitro activities for all other compounds that were evaluated only against BoNT/A LC are given in Supporting Information (Table S1).

We employed a well-defined 17-mer peptide (termed P39, acetyl-SNKTRIDEANQRATKML-amide, that contains the SNAP-25 scissile bond)³⁵ HPLC-based proteolytic assay. Synthesized steroidal derivatives have shown BoNT/A LC inhibition up to 85% at a standard 20 μ M concentration (compound **18**) and IC₅₀ values ranging from 0.7–7.1 μ M (Table 1, Table S1). Our control compound **1**, in the current proteolytic HPLC-based assay showed 90% inhibition of BoNT/A LC at 20 μ M, in excellent agreement with results reported previously (95% of inhibition).¹⁶ Compound **24** with hydroxy groups at C(7) and C(12), with 48% inhibition of BoNT/A LC appeared to be much less potent than other steroidal derivatives. The negative effect of the amide functionality on BoNT/A LC inhibition (**30**, 37%) was also observed. Introduction of a methyl group into the linker or secondary nitrogen and changing its position, as well as the variations in the presence of chlorine atom at the quinoline moiety influenced the inhibitory activity to certain extent.

Benzothiophene derivatives showed good inhibition activities too, with IC₅₀ values ranging within 3.3–10.2 μ M, thus being comparable to the steroidal series. By changing the position of cyano group from C(6) to C(5) the inhibition at 20 μ M concentration was sharply improved (Table 1, Table S1, compounds **36** (61%), **87** (75%), **86** (84%) vs **88** (23%), **89** (8%)).

Derivatives with cyano group instead of fluorine atom at C(5), showed higher degree of inhibition (Table 1, Table S1, compounds **86** (84%), **87** (75%) vs **35** (34%), **90** (56%)), while the compounds without tertiary nitrogen appeared to be more active at 20 μ M concentration than their methylated analogs (Table 1, Table S1, compounds **91** (69%), **36** (61%) vs **92** (48%), **38** (27%)). In thiophene series, the most potent inhibitors proved to be **46** and **93** with cyano substituent and long methylene linker (6 and 8 methylene groups and 70–80% and 77% of inhibition, respectively). Compound **46** (**MV150**) with 70–80% of inhibition has been utilized as positive control, for evaluating the performance of the 17-mer HPLC-based proteolytic assay. Changing the position of aminoquinoline linker connection to phenyl moiety from *para*- to *meta*- had no significant effect on inhibitory activity (Table 1, **46** (70–80%) vs **50** (68%)). Improvement of the inhibitory activity was observed in derivatives without chlorine atom at C(7) position of aminoquinoline or without tertiary nitrogen (Table 1, Table S1, compounds **93** (77%), **46** (70–80%) vs **94** (14%), **95** (30%) and **96** (35%), **48** (55%)). In addition, cyano derivatives were found to be superior inhibitors than their ethynyl analogs (Table 1, Table S1, compounds **97** (36%), **46** (70–80%) vs **47** (19%), **98** (53%)). Examined adamantane derivatives bearing chlorine atom on aminoquinoline moiety proved to be more active in the HPLC-based proteolytic assay than their des-chloro analogs (Table 1, Table S1, compounds **57** (71%), **60** (67%), **99** (64%) vs **69** (31%), **85** (51%), **100** (42%) and other analogs), and that differs from the previously mentioned thiophene series. Tertiary nitrogen and chlorine atom at C(7) of aminoquinoline moiety

together had the most favorable effect on the inhibitory activity (**57** and **60**, 71% and 67% of inhibition, respectively, Table 1).

In addition, experimental $\log D$ values are presented in Table 1. $\log D$ values are obtained using reversed-phase thin-layer chromatography at two different pH: pH=1 (MeOH/HCl (70/30)) for compounds **14–19**, **24**, **46**, **50**, **93**, **96** and **101** and pH=10 (acetone/NH₃/H₂O (85/5/10)) for compounds **34**, **36–38**, **57**, **60**, **86**, **87**, **91**, **102–106**.³⁶ For compound **16** $\log D$ was also determined at physiological pH=7.3, using shake flask method (octanol/TBS buffer).^{37–39}

Inhibitory Activity Against Holotoxin in mES-MNs

Pre-intoxication model—Based on the activity in primary screen and structural diversity (Table 1, Table S1), 30 compounds were chosen for secondary screening in cell-based assay in mouse ES-cell derived motor neurons (mES-MNs) in pre-intoxication model at two concentrations – 10 and 20 μ M (Table 1). SNAP-25 protein cleavage was measured by Western-blot analysis. In this model, compounds were added 30 minutes prior to holotoxin (500 pM) and intoxicated for 4 hours. Inhibitors tested during BoNT/A challenge in mES-MNs in pre-intoxication model were found to afford uncleaved SNAP-25 up to 88% at 20 μ M concentration (compound **16**), with steroidal compounds being generally the most promising.

In contrast to in vitro results, using this assay we can substantially differentiate our steroidal inhibitors from benzothiophene derivatives, which were capable to protect SNAP-25 from cleavage up to 68% at 20 μ M concentration. Another issue is important to note – benzothiophene derivatives (**36**, **86** and **87**) with cyano instead of fluorine substituent were much less active despite the high percent of inhibition in HPLC-based assay. In addition, in this model the compound **38**, shows significantly higher protection of SNAP-25 in comparison with non-methylated analogues, although it would be eliminated based on its poor inhibitory activity (27%) in primary screening. Three thiophene derivatives have shown to be capable of protecting SNAP-25 from cleavage more than 60% at 20 μ M concentration (**50**, **93** and **96**), while adamantane derivatives were found to be less active, despite promising results obtained in primary screening. Only one adamantane **60**, showed 72% protection of SNAP-25 at 20 μ M.

Twelve compounds with good results obtained in pre-intoxication model (56–88% SNAP-25 protection at 20 μ M concentration, Table 1) were subjected to pre-exposure dose-response experiment in concentration range from 0.1 to 20 μ M (Figure 1). The results obtained in dose-response experiment at 20 μ M concentration are similar to those obtained in the initial experiment at two concentrations, given in Table 1. The obtained dose-response results clearly indicate that introduction of chlorine atom at C(7) position of quinoline moiety highly improved the activity of steroidal inhibitors (**16** vs **14**; IC₅₀ ~ 10 μ M vs IC₅₀ = 10–20 μ M, respectively). Another pair of derivatives, **19** with methyl group next to N-C(24) and **17** with methyl group next to quinoline moiety, also merit attention. Significantly higher protection of SNAP-25 is observed with **19** at 20 μ M concentration, while at lower concentrations both derivatives exhibited comparable inhibitory activity. Except mentioned

four steroidal derivatives, compound **1** showed remarkable activity in pre-intoxication scenario ($IC_{50} < 10 \mu M$). As the inhibitor **24** could arise as putative metabolite in vivo, despite its lower activity in HPLC-proteolytic assay compared to other steroidal derivatives, we were intrigued by moderate activity of this compound in pre-intoxication model (58% at $16 \mu M$, Table 1). Tested at nine concentrations 0.25 to $64 \mu M$ it also showed dose-dependent behavior, with $IC_{50} = 8\text{--}16 \mu M$ (Figure S1, Table S5). Benzothiophene derivatives **34** and **38** showed IC_{50} values in $10\text{--}20 \mu M$ range. In addition, three thiophene (**50**, **93** and **96**) and two adamantane (**57** and **60**) 4-aminoquinoline derivatives were evaluated in dose-dependent pre-intoxication model, in order to examine the scope of carriers coupled to aminoquinoline moiety. To our pleasure, not only steroidal and benzothiophene aminoquinolines showed remarkable activities in dose-dependent manner, but also thiophene and adamantane derivatives. As one can find in Figure 1, **60** has shown the highest protection of SNAP-25 at $20 \mu M$ concentration (90%) and $IC_{50} < 10 \mu M$. Good dose-response and high percent of inhibition is also seen for **93** and **96** ($IC_{50} = 10\text{--}20 \mu M$ and $IC_{50} = 5\text{--}10 \mu M$, respectively).

Post-intoxication model—The most effective derivatives were tested post-symptomatically (in triplicate, 30 and 60 minutes following 500 pM holotoxin administration) at 20 pM concentration (Figure 2). Compound **60**, which was the foremost candidate in pre-intoxication model, unfortunately failed in post-exposure model with only 15% of intact SNAP-25. From all tested derivatives, compound **16** highlights with 64% of SNAP-25 cleavage protection when administered 30 minutes post-intoxication, and 45% protection when neurons were treated 60 minutes after BoNT/A administration. Other derivatives were significantly less active, with steroidal series still being the most promising.

Since compound **16** showed excellent behavior in post-intoxication scenario (Figure 2 and Figure S2, Table S6), and compound **24** is considered as a potential metabolite which is reasonable to expect to be formed in mouse gut and liver, we subjected both **16** and **24** to 30 minutes post-exposure dose-response experiment. Compounds were tested in duplicate at 9 concentrations, starting from $0.25 \mu M \rightarrow 64 \mu M$ (Figure 3). In this run **16** exhibited a dose-dependent protection of SNAP-25, with $IC_{50} \sim 8 \mu M$. To the best of our knowledge, this is the most active small-molecule inhibitor of BoNT/A LC in post-intoxication scenario in mES-MNs (89% of full length SNAP-25 at $32 \mu M$). The activity of compound **24** in mES-MNs (69% full length SNAP-25 at $64 \mu M$) was somewhat surprising; however, observation that both, the compound **16** and its putative metabolite were active in mES-MNs strongly supports further examination of biological activity.

Toxicity studies

In vivo toxicity studies of several derivatives subjected to post-intoxication assay was estimated in a mouse model. As can be seen from Table 2, **16**, **34**, **93** and **96** proved to be completely non-toxic at the given dose (all 5 mice survived 30 days after administration and showed normal appearance and behavior).

In the separate host toxicity studies, two groups of 5 healthy mice were subjected to oral administration of the compound **16** at higher concentrations (400 and 600 mg/kg , single

dose), and even at the highest applied concentration, **16** proved to be non-toxic (all 5 mice survived 30 days after administration and showed normal appearance and behavior).

Pharmacokinetic Analysis of Compound **16**

ADMET parameters—Given its ability to antagonize BoNT/A in mES-MNs in post-intoxication model (in full accordance with previous step analyses), **16** appeared as the best candidate for further testing. ADMET parameters for this compound are presented in Table 3. Compound **16** showed good stability in both human and mouse liver microsomes (half-life >60 min) and very good stability in human plasma (>85% remaining at 1 h). It showed solubility >50 µg/mL (Table 3) as determined by laser nephelometry and confirmed by more precise shake-flask method with spectrofluorimetric detection (640 µg/mL). In MDR1-MDCK permeability assay, **16** showed excellent tissue penetration (45.3×10^{-6} cm/s in A→B direction and 24.6×10^{-6} cm/s in B→A direction). It acts as moderate to poor inhibitor of five CYP450 enzymes (which play important role in the drug metabolism). One in vitro parameter possibly limiting this compound as potential drug is high plasma protein binding, >99% according to equilibrium dialysis method. However, the efficacy of the drug transport could not be attributed to the PPB only; instead, the binding constants with major transporters in the blood should be considered. In addition to dialysis, the interaction between **16** and HSA and AGP proteins has been studied by monitoring the changes in fluorescence spectrum of HSA and AGP upon addition of increasing amounts of **16** ($K_{sv} = (4.56 \pm 0.27) \times 10^4$ for HSA; $K_{sv} = (6.99 \pm 0.25) \times 10^5$ for AGP).

In Vivo Mouse Pharmacokinetics—Aminoquinoline **16** was selected for determination of concentration levels in mouse serum and evaluation of plasma protein binding due to its promising activity in mES-MNs, non toxicity, and very good ADMET properties. Compound **16** was dosed orally, in a single dose, at two different concentrations – 400 and 600 mg/kg to groups of 7 and 6 mice, respectively. For both doses, maximal concentration of the drug in the blood was determined by UPLC-MS/MS in samples previously treated with acetonitrile (15 → 120 min, Table 4 and Figure 4).

Obtained in vivo pharmacokinetic properties are summarized in Table 5. In addition, mice samples were analyzed for compound **24**, monoacetylated analogue and corresponding M +16 and M+32 metabolites, in order to examine possible deacetylation in the mouse gut. None of these metabolites were detected.

DISCUSSION

Logical step in the investigation of drug's anti BoNT/A potential was the evaluation of the candidates in a cell-based assay using mES-MNs, since they mimic the whole intoxication process. We proved that our inhibitors protect SNAP-25 from cleavage in a dose-dependent manner, when administered prior to holotoxin (Figure 1). Thiophene derivative **96** has shown the $IC_{50} = 5-10$ µM, benzothiophene derivatives **34** and **38** $IC_{50} = 10-20$ µM and among steroidal derivatives **16** singled out with $IC_{50} \sim 10$ µM. Adamantane derivative **60** seemed to be the favorable candidate with 90% of SNAP-25 protection at 20 µM and $IC_{50} < 10$ µM. The discrepancy between results obtained in proteolytic HPLC-based assay and in

mES-MNs for cyano derivatives **36**, **86** and **87** (61–84% inhibition vs 26–53% SNAP-25 protection at 20 μ M) could be attributed to their inability to enter the neurons. Regarding compound **38** different MoA might be considered since this compound does not act as LC inhibitor (27% inhibition, Table 1) but it moderately protects SNAP-25 in mES-MNs in pre-intoxication scenario (IC_{50} = 10 20 μ M, Figure 1).

Pre-exposure model for BoNT/A intoxication is very convenient for discovering drugs with good permeability, and the results of inhibitory activities could be useful for prophylactic purposes. More significant challenge is post-exposure model, which demonstrates the ability of compound to protect SNAP-25 from BoNT/A cleavage after holotoxin endocytosis. Noteworthy results of our inhibitors in post-intoxication model in mES-MNs offered us valuable information that newly synthesized derivatives not only enter the cells, but also very probably inhibit to great extent the BoNT/A LC inside the neuronal cytosol. From all examined derivatives, we managed to select steroidal compound **16** which antagonizes BoNT/A holotoxin up to 89% at 32 μ M when administered 30 minutes post-intoxication. More importantly, the essential difference between our previous hit *bis*-ACQ compounds came out – compound **1** with < 40% protection failed in post-intoxication scenario, thus justifying the synthesis of novel C(3)-amino derivatives.

In the early stages of drug discovery, the optimization of physicochemical properties (e.g. lipophilicity) can greatly improve a compound's chance in obtaining the proper balance among permeability, solubility and metabolism; and the experimental $\text{Log}D$ of 2.07 (pH=7.3) obtained for compound **16** was considered optimal in that regard.⁴¹ Subsequent ADMET and PK studies were performed in order to determine if compound **16** was capable of providing adequate drug exposure. As supported by its $\text{Log}D$ value, compound **16** displayed favorable ADMET properties. In an MDR1/MDCK assay it showed permeability constant P_{app} >20, predictive for good tissue penetration and the efflux ratio << 2.5, thus not being a substrate for P-gp. PPB for this compound was estimated to >99% according to equilibrium dialysis method, however, spectrofluorimetric measurements of **16** binding for HSA and AGP, indicate that interaction between **16** and plasma proteins is optimal to enable transport of the drug and to release it at its target (K_{sv} = 10^4 – 10^6). This experimental observation is supported by detailed reviews on albumin-drug and AGP-drug interactions.^{42–44} Due to its nontoxicity in vivo at very high concentration (up to 600 mg/kg), we provided pharmacokinetic analysis in mice. Compound **16** administered at 600 mg/kg dose provides C_{max} up to 11.9 μ M (8.5 μ g/mL, Table 4) and is detectable in mouse serum up to 120 min after administration (Figure 4). Unfortunately, detailed PK analysis was published only for few inhibitors submitted to in vivo studies, so detailed analysis and comparison with **16** is not possible.⁴

CONCLUSION

Synthesized compounds antagonize BoNT/A LC and BoNT/A in mES-MNs in a dose-dependent manner in both pre- and post-intoxication models. To the best of our knowledge, this is the first example of LC inhibitors antagonizing BoNT intoxication in mouse ES-cell derived motor neurons in a post-exposure model (few SMNPIs of BoNT/A LC active in embryonic chick spinal motor neurons were reported previously⁴⁵). Compound **16** proved to

be potent inhibitor of BoNT/A holotoxin in mES-MNs in post-intoxication scenario and well tolerated in the mouse up to 600 mg/kg, p.o. Binding constants with major transporters in blood (HSA and AGP) are within desirable values, suggesting that in spite of high PPB it could be delivered to its target. With very good ADMET properties and a plasma C_{max} >10 μ M in mice after oral administration, we believe that compound **16** has distinguished itself from other lead BoNT inhibitors in the literature.⁴ Current efforts are focused on reducing protein binding, determining/mitigating the clearance route of **16** in mouse and determining if optimal formulation and/or subcutaneous administration could improve its PK profile and merit testing in a mouse lethality model. Noteworthy, there are no post symptomatically administered LC inhibitors to date that are significantly efficacious in a mouse model of BoNT intoxication.⁴

EXPERIMENTAL SECTION

Chemistry

Melting points were determined on a Boetius PMHK apparatus and were not corrected. IR spectra were recorded on a Thermo-Scientific Nicolet 6700 FT-IR diamond crystal spectrophotometer. ¹H and ¹³C NMR spectra were recorded on a Varian Gemini-200 spectrometer (at 200 and 50 MHz, respectively), and a Bruker Ultrashield Advance III spectrometer (at 500 and 125 MHz, respectively) in the indicated solvent (vide infra) using TMS as the internal standard. Chemical shifts are expressed in ppm (δ) values and coupling constants (*J*) in Hz. ESI-MS (HRMS) spectra of the synthesized compounds were acquired on a Agilent Technologies 1200 Series instrument equipped with Zorbax Eclipse Plus C18 (100 $\times$ 2.1 mm i.d. 1.8 μ m) column and DAD detector (190–450 nm) in combination with a 6210 Time-of-Flight LC/MS instrument in positive and negative ion mode. The samples were dissolved in MeOH (HPLC grade). The selected values were as follows: capillary voltage 4 kV; gas temperature 350 $^{\circ}$ C; drying gas 12 L min⁻¹; nebulizer pressure 45 psig; fragmentator voltage: 70 V. Mass spectral analyses were done using electrospray ionization in positive ion mode on a Surveyor separations module coupled to a ThermoFinnigan TSQ AM triple quadrupole mass spectrometer. Gas chromatography tandem mass spectrometry (GC-MS) analyses were performed on an Agilent 7890A GC (Agilent) system equipped with a 5975C inert XL EI/CI MSD and a flame ionization detector (FID) connected by capillary flow technology through a 2-way splitter with make-up gas. An HP-5 MS capillary column (Agilent Technologies, 25 mm i.d., 30 m length, 0.25 μ m film thickness) was used. The flash chromatography was performed on Biotage SP1 system equipped with UV detector and FLASH 12+, FLASH 25+ or FLASH 40+ columns charged with KP-SIL (40 – 63 μ m, pore diameter 60 $\text{\AA}$), KP-C18-HS (40 – 63 μ m, pore diameter 90 $\text{\AA}$) or KP-NH (40 – 63 μ m, pore diameter 100 $\text{\AA}$) as an adsorbent. Elemental analyses were realized with an Elemental Vario EL III microanalyser. Compounds were analyzed for purity (HPLC) using a Agilent 1200 HPLC system equipped with Quat Pump (G1311B), Injector (G1329B) 1260 ALS, TCC 1260 (G1316A) and Detector 1260 DAD VL+ (G1315C). Compound **42** was analyzed for purity (HPLC) using Waters 1525 HPLC dual pump system equipped with an Alltech, Select degasser system, and dual λ 2487 UV VIS detector. All tested inhibitors were fully characterized and their purities were >95% (as determined by HPLC, c.f. Supporting Information). HPLC analysis was performed in two diverse systems for each

compound. Specific HPLC methods are as follows: **Method A:** Zorbax Eclipse Plus C18 4.6 × 150 mm, 1.8 μ , S.N. USWKY01594 was used as the stationary phase. Eluent was made from the following solvents: 0.2% formic acid in water (A) and methanol (B). The analysis were performed at the UV max of the compounds (at 330 nm for compounds **14–16, 18, 19, 22, 23, 34, 37, 38, 50, 56–65, 66–69, 77–82, 84, 85** and **93**, and at 254 nm for compound **17**) to maximize selectivity. Compounds were dissolved in methanol, final concentrations were ~1 mg/mL. Flow rate was 0.5 mL/min. **Method B:** Zorbax Eclipse Plus C18 4.6 × 150 mm, 1.8 μ , S.N. USWKY01594 was used as the stationary phase. Eluent was made from the following solvents: 0.2% formic acid in water (A) and acetonitrile (B). The analysis were performed at the UV max of the compounds (at 330 nm for compounds **14–19, 22, 23, 34, 37, 38, 44, 50, 56–65, 66–69, 77–82, 84, 85** and **93**) to maximize selectivity. Compounds were dissolved in methanol, final concentrations were ~1 mg/mL. Flow rate was 0.5 mL/min. **Method C:** Zorbax Eclipse Plus C18 2.1 × 100 mm, 1.8 μ , S.N. USUXU04444 was used as the stationary phase. Eluent was made from the following solvents: 0.2% formic acid in water (A) and methanol (B). The analysis was performed at the UV max of the compound (at 330 nm for compounds **20, 21, 24, 43, 44, 47**; at 270 nm for compound **30**, and at 254 nm for compound **33**) to maximize selectivity. Compound was dissolved in methanol, final concentration was ~1 mg/mL. Flow rate was 0.2 mL/min. **Method D:** Zorbax Eclipse Plus C18 2.1 × 100 mm, 1.8 μ , S.N. USUXU04444 was used as the stationary phase. Eluent was made from the following solvents: 0.2% formic acid in water (A) and acetonitrile (B). The analysis was performed at the UV max of the compound (at 254 nm for compounds **20, 24, 33**; at 270 nm for compound **30** and at 330 nm for compounds **21, 43** and **47**) to maximize selectivity. Compound was dissolved in methanol, final concentration was ~1 mg/mL. Flow rate was 0.2 mL/min. **Method E:** Poroshell 120 EC-C18, 4.6 × 50mm, 2.7 μ , S.N. USCFU07797 was used as the stationary phase. Eluent was made from the following solvents: 0.2% formic acid in water (A) and acetonitrile (B). The analysis was performed at the UV max of the compound (330 nm for compound **48**) to maximize selectivity. Compound was dissolved in methanol, final concentration was ~1 mg/mL. Flow rate was 0.5 mL/min. **Method F:** Poroshell 120 EC-C18, 4.6 × 50mm, 2.7 μ , S.N. USCFU07797 was used as the stationary phase. Eluent was made from the following solvents: 0.2% formic acid in water (A) and methanol (B). The analysis was performed at the UV max of the compound (330 nm for compound **48**) to maximize selectivity. Compound was dissolved in methanol, final concentration was ~1 mg/mL. Flow rate was 0.5 mL/min. **Method G:** Symmetry C18, 4.6 × 150 mm, 5 μ m, S.N. 021336278136 37 was used as the stationary phase. Eluent was made from the following solvents: 0.2% formic acid in water (A) and methanol (B). The analysis was performed at the UV max of the compound (340 nm for compound **42**) to maximize selectivity. Compound was dissolved in methanol, final concentration was ~1 mg/mL. **Method H:** Nucleosil C18, 4 × 150 mm, 5 μ m was used as the stationary phase. Eluent was made from the following solvents: 0.2% formic acid in water (A) and methanol (B). The analysis was performed at the UV max of the compound (340 nm for compound **42**) to maximize selectivity. Compound was dissolved in methanol, final concentration was ~1 mg/mL.

Procedure A: General procedure for the synthesis of *N*-Cbz protected aminoquinolines 107 and 109¹³

The mixture of 4,7-dichloroquinoline/4-chloroquinoline (1 equiv) and mono-Cbz protected diaminoalkane (1.1 – 1.2 equiv) was slowly heated to 80 °C for 1 h, and the mixture was continued for 6–8 h at 120–130 °C. After cooling to r.t., reaction mixture was transferred to the separation funnel using CH₂Cl₂/1M NaOH. The organic layer was washed with 1M NaOH, water and brine. The organic layer was dried over anhydrous Na₂SO₄ and solvent was evaporated under reduced pressure. Crude product was purified using column chromatography.

Procedure B: General procedure for the obtainment of steroidal derivatives 4-11 and 29¹⁶

Alcohol (1 equiv) was dissolved in CH₂Cl₂. PCC (1.5 equiv) was added, and the mixture was stirred at r.t. for 3.5 h. Reaction mixture was filtered through a short column of SiO₂ (eluent CH₂Cl₂/EtOAc = 7/3). Crude aldehyde was dissolved in dry MeOH, aminoquinoline (1.5 equiv) was added, and mixture was stirred at r.t. overnight. NaBH₄ (2 equiv) was added, and stirring was continued at r.t. for 12 h. Solvent was removed under reduced pressure and crude mixture was prepared for column purification.

Procedure C: General procedure for the removal of the Boc-protecting groups with TFA for compounds 14-23 and 30

A solution of the *N*-Boc protected amine in TFA/CH₂Cl₂ (v:v; 1:10), was stirred at r.t. for 6 h. Solvents were evaporated under reduced pressure and the residue was treated with CH₂Cl₂/2.5M NaOH. The organic layer was dried over MgSO₄, and the solvent was evaporated under reduced pressure.

Procedure D: General procedure for *N*-methylated aminoquinolines 12, 13, 37, 38, 48, 56-65, 68, 69 and 84, 85⁴⁶

To a stirred solution of aminoquinolines (1 equiv) in MeOH containing 37% aqueous formaldehyde (2 equiv), the mixture of ZnCl₂ (2 equiv) and NaHB₃CN (4 equiv) in MeOH was added. After the reaction mixture was stirred at r.t. for 4 h, the solution was taken up in 0.1 M NaOH and most of MeOH was evaporated under reduced pressure. Aqueous solution was extracted with CH₂Cl₂, the combined extracts were washed with water and brine and dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure.

Procedure E: General procedure for reductive amination to produce compounds 33, 34, 42-45, 50, 66 and 67

Amine (1.5 equiv) and appropriate aldehyde (1 equiv) were dissolved in MeOH/CH₂Cl₂ mixture (v:v; 2:1), glacial AcOH (1.5 equiv) was added, and the mixture was stirred under Ar atmosphere at r.t. After 3 h, NaBH₄ (6 equiv) was added, and stirring was continued for another 18 h. Solvent was removed under reduced pressure, and the residue was dissolved in CH₂Cl₂. The organic layer was washed with 2M NH₄OH, water and then extracted with CH₂Cl₂. The combined organic layers were washed with brine and dried over anhydrous Na₂SO₄. Finally, the solvent was evaporated under reduced pressure.

Procedure F: General procedure for the Suzuki coupling reaction using PdO × 1.4 H₂O for compounds 40 and 113.⁴⁷

An appropriate aryl bromide (1 equiv) was added to the mixture of arylboronic acid (1.2 equiv), catalyst PdO × 1.4 H₂O (0.1 equiv), K₂CO₃ (1.2 equiv) and EtOH/H₂O (3:1, v/v). The mixture was stirred at 60 °C for 5 h, then diluted with water and extracted with CH₂Cl₂. Combined organic layers were washed with brine and dried over anhydrous Na₂SO₄. After filtration, the solvent was removed under reduced pressure. The product was purified using silica gel flash chromatography.

Procedure G: General procedure for the Suzuki coupling reaction using Pd(OAc)₂ and PPh₃ for compounds 49 and 111

The solution of Pd(OAc)₂ (0.1 equiv) and PPh₃ (0.4 equiv) in DME was purged with argon and stirred at r. t. for 10 min. An appropriate arylboronic acid (1 equiv) and 2M aq. Na₂CO₃ were added. After 5 min, aryl-bromide (1 equiv) was added. The mixture is once more purged with Ar and heated in a sealed vessel in microwave reactor at 80 °C for 3h. The reaction mixture was cooled and extracted with ethyl-acetate. The combined organic layers were washed with brine and dried over anhydrous Na₂SO₄. After filtration, the solvent was removed under reduced pressure. The crude product was further purified in a manner provided for each compound.

Procedure H: General procedure for palladium catalyzed amination of quinolines to produce compounds 78, 79, 81 and 82

Vial was charged with mixture of Pd(OAc)₂ (4 mol %) and DPEphos (8 mol %)/SPhos (8 mol %) in dioxane and stirred for a few minutes in Ar atmosphere on room temperature. Subsequently, haloquinoline (1.0 equiv), amine (1.2 equiv) and K₃PO₄ (2.5 equiv) were added in to reaction mixture. The resulting suspension was sparged with argon for several minutes. The vial was quickly capped, heated to 85 °C over the night and then cooled down to room temperature. The mixture was adsorbed onto silica gel and purified.

N-(quinolin-4-yl)ethane-1,2-diamine (**AQ11**), *N*-(7-chloroquinolin-4-yl)butane-1,4-diamine (**AQ4**), *N*-(7-chloroquinolin-4-yl)hexane-1,6-diamine (**AQ6**), *N*-(quinolin-4-yl)propane-1,3-diamine (**AQ7**), *N*-(quinolin-4-yl)butane-1,4-diamine (**AQ8**), *N*-(quinolin-4-yl)hexane-1,6-diamine (**AQ9**), *N*-quinolin-4-yldecane-1,10-diamine (**AQ12**) were prepared according to known procedures.^{48–51}

In vitro HPLC-based Proteolytic Assay for BoNT/A LC Inhibition

BoNT/A LC 17-mer HPLC endpoint assay in 96well plate (manual method) uses 2.5mM stock solution of the 17-mer peptide (termed P39, acetyl-SNKTRIDEANQRATKML-amide) in 50 mM HEPES, pH 7.4 For the inhibitor, the final concentration was 20 μM, diluted from a working stock of 120 μM in 50 mM HEPES pH 7.4. Just prior to conducting the assay, LcA was diluted to 0.1 mg/mL in 50 mM HEPES pH 7.4 and kept on ice. Final concentrations for the assay are as follows: [LcA] = 1.95 μg/mL (20 nM), [BSA] = 0.2 mg/mL, [P39] = final conc. 0.25mM, [Inhibitor] = 20 μM in a total reaction volume of 30 μL. The assay is conducted as follows. The compound (5 μl of the 120 μM working stock) is

incubated with the LcA master mix (LcA and BSA in 50mM HEPES) and incubated for 10 minutes at room temperature. The P39 substrate is then added and the samples are incubated at 37°C for 10 minutes. Cleavage products of the P39 substrate are monitored and quantitated using a Shimadzu Prominence ultra fast liquid chromatography (UFLC) XR system using a Hypersil Gold Javelin (Thermo Fisher Scientific, Waltham, MA) c18 guard column and a Hypersil Gold (Thermo Fisher Scientific, Waltham, MA) c18 reverse-phase analytical column (50 × 2.1 mm, 1.9 μm). Flow rate of 1.000 ml/min. Column chamber oven temp 65°C. Monitor absorbance at 214 nm and 280 nm. The solvents and gradient are as follows: Buffer A = HPLC grade water + 0.05% Trifluoroacetic acid; Buffer B= 50% HPLC grade Acentonitrile + 0.05% Trifluoroacetic acid. All HPLC separations were conducted and peak areas measured with the LC solution automated integration software (Shimadzu Corporation, Kyoto, Japan). For BoNT/A, the fragment peaks retention times were ≈ (0.9–1.1 min) and (1.3–1.5 min). Percent inhibition of each compound tested was calculated using the following formula: $100 - (\Sigma \text{ of fragment peak areas} + \text{compound} / \Sigma \text{ of fragment peak areas} - \text{compound}) \times 100$.

Derivation of motor neurons from mouse embryonic stem cells

We have utilized a specific mouse embryonic stem (ES) cell (HBG3) line, in which mouse motor neuron specific Hb9 promotor drives eGFP expression, to generate motor neurons. The specifics regarding the culture, differentiation and maintenance of these cells, and the characterization of derived motor neurons have been published.^{52,53}

BoNT intoxication, Inhibitor Application and Western blot analysis for the BoNT mediated SNAP-25 cleavage determination

For pre intoxication studies, the motor neurons differentiated from mouse ES cells were cultured in 24-well plates and treated with the indicated amounts of compounds in the figures. Following a 30 min incubation, the cultures were intoxicated with 500 pM BoNT/A (MetaBiologics, Madison, WI). For post intoxication studies, the cultures were first intoxicated with 500pM BoNT/A and then the compounds were applied to the plates 30 or 60 min after the intoxication. In both pre and post intoxication models, total intoxication time was kept constant as 4 hours and the neurons were maintained at 37 °C cell culture humidified incubators with 5% CO₂ atmosphere. The cells were then washed with PBS thoroughly, and lysed in NP-40 cell lysis buffer. The extent of SNAP-25 cleavage was quantified using standard immunoblotting procedures with SNAP-25 antibodies that detect both the full length and the BoNT/A cleaved large fragment, as described previously.^{7,10} Briefly, the cell lysates were processed, run on 12% Tris Glycine gels (Invitrogen, #XP00125), and transferred to nitrocellulose membranes. Membranes were blocked in 5% non-fat milk for 1hr, and then incubated with primary antibodies against GAPDH (Millipore, #MAB374), and SNAP-25 (BioLegend, SMI-81, #836304) in TBST buffer containing 5% milk overnight at 4 °C. Horse radish peroxidase conjugated secondary antibodies (Millipore) were utilized for the detection of the signal. The blots were visualized with Pierce ECL Western detection kit, using a gel documentation and analysis system.

Log D (shake-flask) metod

Standard shake-flask method was used for log D (pH 7.31, 30 mM TBS) determination.^{37–39} Stock solution of **16** was prepared in octanol ($c = 2.5 \times 10^{-3}$ M).

Toxicity studies: in vivo

Groups of five healthy mice were treated per os (p.o.) for three consecutive days with aminoquinolines suspended in 0.5% hydroxyethylcellulose –0.1% Tween 80, previously dissolved in DMSO. Individual mouse behavior and appearance was monitored two times a day for 30 days. Compounds proved to be non-toxic if all 5 mice survived 30 days after administration and showed normal appearance and behavior.

The study followed the International Guiding Principles for biomedical research involving animals, and was reviewed by a local Ethics Committee and approved by the Veterinary Directorate at the Ministry of Agriculture and Environmental Protection of Serbia (decision no. 323 07 02444/2014 05/1).

In vitro Plasma Protein Binding (Equilibrium dialysis for **16**)

In vitro plasma protein binding was performed by the ADME Center at USAMRICD using Thermo Scientific's protocol and their Single-Use RED (rapid equilibrium dialysis) Plates. Samples (100–500 μ L) were prepared by spiking test compound with plasma at the appropriate concentrations and places into the sample chamber. Dialysis buffer (300–750 μ L) was added to the buffer chamber. The unit was covered with sealing tape and incubated at 37°C on an orbital shaker at approximately 250 rpm or 20 rpm on an up and down shaker for 4h. 50 μ L from both the buffer and the plasma chambers were placed in separate microcentrifuge tubes or into a deep well plate for analysis. 50 μ L of plasma was added to the buffer sample and an equal volume of buffer to the collected plasma sample. 300 μ L of Internal Standard containing precipitation buffer (such as cold 90/10 acetonitrile/water with 0.1% formic acid) was added to precipitate protein and release compound. Vortexed and incubated 30 minutes on ice, centrifuged for 10 minutes at 13,000–15,000 $\times g$. The supernatant was analyzed with LC-MS/MS. The test compound concentration in the buffer and plasma chambers were determined from peak areas relative to the internal standard. The percentage of the test compound bound was calculated as follows: % Free = (Concentration buffer chamber/Concentration plasma chamber) $\times$ 100%. % Bound = 100% - % Free.

In vitro Plasma Protein Binding (Spectrofluorimetric determination for compound **16**)

Human serum albumin (HSA), alpha-1-acid glycoprotein (AGP), potassium dihydrogen phosphate, disodium hydrogen phosphate, sodium chloride, potassium chloride and DMSO were purchased from Sigma-Aldrich. Fluorescence spectra were recorded on Horiba Jobin Yvon Fluoromax-4 spectrometer, equipped with Peltier element and magnetic stirrer for cuvette, using quartz cell with 1 cm path length and 4 mL volume. UV-Vis spectra were recorded on Thermo scientific spectrophotometer evolution 60s using quartz cell with 1 cm path length and 4 mL volume. All UV/Vis spectra were recorded against the corresponding blank in the 200–500 nm wavelength range, with 500 nm/min scan speed. pH Values were potentiometrically measured using Crison pH-Burette 24 2S equipped with a micro-

combined pH electrode (Crison pH electrode 50 29). The pH electrode was calibrated by standard Crison buffer solutions (pH 4.01, 7.00, and 9.21). Stock solutions of AGP ($c=6.05 \times 10^{-5}$ M) and HSA ($c=1.91 \cdot 10^{-4}$ M) were prepared in PBS (1X, pH 7.34) and kept in the refrigerator. Stock solution of **16** ($c=4.28 \times 10^{-4}$ M) was prepared in DMSO. For protein-**16** interaction studies, protein solutions were freshly prepared from the stock, by dilution with a buffer (AGP and HSA concentration was kept constant, $c=5 \times 10^{-7}$ M), and titrated with compound stock solution (from 1 to 20 compound/protein molar ratio). During the titration, the solutions were stirred and thermostated ($t=25.0 \pm 0.1^\circ\text{C}$, regulated by Peltier element). The equilibration time between increment additions was 10 minutes. An excitation wavelength was 280 nm, with 5 nm slits; emission spectra were recorded in 300–450 nm wavelength range, with 5 nm slits, and 0.1 s integration time. Background PBS signal was subtracted from each spectrum. Fluorescence intensities were corrected for inner filter effect by measuring absorbances at excitation and emission wavelength.

In vivo Mouse Pharmacokinetics

Compound **16** was dissolved in DMSO, suspended in 0.5% hydroxyethylcellulose – 0.1% Tween 80 in water and administered orally at two different concentrations. Blood was collected from one mouse, previously anaesthetized with chloroform, for each time point via cardiac puncture. Samples were immediately centrifuged and serum stored at -20°C until the moment of analysis. Human serum was collected from a healthy volunteer and stored in refrigerator at 4°C . Total concentrations of compound in mice samples were determined by precipitation of proteins by addition of two volume equivalents of acetonitrile (50 μL of sample and 100 μL of acetonitrile), following 15 seconds on vortex and 30 minutes in ultrasound bath. After centrifugation of denatured proteins (10 minutes, 13400 rpm), supernatants were injected. For determination of free concentration, ultracentrifugation method was used. 150 μL of mice samples were centrifuged on Beckman Coulter ultracentrifuge (rotor type SW55 Ti, 25 000 rpm, 24 h, 4°C , 0.8 mL tubes). Mice serum has been separated into three layers, 30 μL of transparent middle layer was taken from each tube via syringe and injected into UPLC-MS/MS. Transparent middle layer showed 1% of starting plasma proteins, as confirmed by BCA method for determination of concentration of proteins. Calibration curves for free and total concentrations were prepared using blank human serum. In case of total concentration, compound standard solutions were prepared in DMSO (250 and 2500 $\mu\text{g/mL}$). Human serum was spiked with stock solutions, final solutions (1 – 25 $\mu\text{g/mL}$) were incubated at 37°C for 1 h and treated with acetonitrile in the same way. For determination of free concentration of the drug, ultracentrifugation method was used. Standard solutions of compound (0.5 – 10 $\mu\text{g/mL}$) were prepared in supernatants obtained by ultracentrifugation of blank human serum. From both experiments, 15–45 min samples were centrifuged on Beckman Coulter ultracentrifuge (rotor type SW55 Ti, 24 h, 4°C , 25000 rpm, 0.8 mL tubes) and analyzed for compound **16**. Concentrations of compound in mice serum were quantitated using a Waters Acquity UPLC H-Class (WAT-176015007) (Milford, MA, USA) with Poroshell 120 EC-C18 column ($4.6 \times 50\text{mm}$, 2.7μ , S.N. USCFU07797) and interfaced to mass detector (Waters TQ (Tandem Quadrupole, WAT-176001263)). Single ion recording experiment (SIR) was used, by monitoring three ions: $[\text{M}+\text{H}]^{1+}$ (709), $[\text{M}+2\text{H}]^{2+}$ (355) and $[\text{M}+3\text{H}]^{3+}$ (237). Column temperature was maintained at 40°C and mobile phase flow rate at 0.3 mL/min. The mobile phase consisted

of ultrapure water (TKA Germany MicroPure water purification system, 0.055 $\mu\text{S}/\text{cm}$) containing 0.2 vol.% formic acid (solvent A) and acetonitrile (solvent B), with a gradient 0–2 min 5%B, 2–8 min 5%B→95%B, 8–12 min 95%B, 12–12.5 min 95%B→5%B, 12.5–15 min 5%B for reconditioning of the column. Injection volume was 10 μL . For detection of total concentration, limit of detection (LOD) was 1 $\mu\text{g}/\text{mL}$ ($S/N > 3:1$), limit of quantitation (LOQ) was 2 $\mu\text{g}/\text{mL}$ ($S/N = 10:1$) and $R^2=0.9952$ (calibration curve was performed in triplicate).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by the National Institute of Allergy and Infectious Diseases (U.S.) Grant 5-U01AI082051-02 (SB, BS, AJD, LHC) and R33-AI101387 (EK, KK, JKT), and by the Ministry of Science and Technological Development of Serbia Grant 172008 (JK, MV, NTJ, TZV, BS), Serbian Academy of Sciences and Arts (BS), and the U.S. Defense Threat Reduction Agency/Joint Science and Technology Office (SB). We thank Dr. Olgica Djurkovi -Djakovi and MSc Jelena Srbljanovi (Institute for Medical Research, University of Belgrade) for help and collaboration with collecting mice blood samples for pharmacokinetics and performing in vivo toxicity studies; MSc Jovana Periša (Vin a Institute of Nuclear Sciences, University of Belgrade) for assistance with synthesis of adamantane derivatives; Dr. Milka Jadranin (Institute of Chemistry, Technology and Metallurgy, University of Belgrade) for optimization of UPLC-MS/MS method and Dr. Milan Koji (Institute of Molecular Genetics and Genetic Engineering, University of Belgrade) for optimization of ultracentrifuge method used for the analysis of mice samples. We also thank Dr. Sandra Šegan (Institute of Chemistry, Technology and Metallurgy, University of Belgrade) for carrying out log*D* experiments using reversed-phase thin-layer chromatography. We thank Dr. Benedict Capacio and colleagues at the ADME Center at the US Army Medical Institute for Chemical Defense for evaluating the ADME properties of compound **16**. B.S. thanks prof. Mario Zlatovi , Faculty of Chemistry, University of Belgrade, for performing docking simulations presented in Supporting Information section.

ABBREVIATIONS

ABS 252	<i>N</i> -(3-(4-fluorophenyl)-1H pyrazol-5 yl)-2-mercaptoacetamide
Dyngo-4a	3-hydroxy- <i>N'</i> -[(1 <i>E</i>)-(2,4,5-trihydroxyphenyl)methylene]-2-naphthohydrazide
EGA	4-bromobenzaldehyde- <i>N</i> -(2,6-dimethylphenyl)semicarbazone
BoNT/A LC	botulinum neurotoxin serotype A light chain
mES-MNs	mouse embryonic stem cell derived motor neurons
SNAP-25	synaptosomal-associated protein 25
SNARE	soluble <i>N</i> -ethylmaleimide-sensitive fusion attachment protein receptor
SMNPI	small molecule non-peptidic inhibitors
AQn	<i>N</i> -(7-chloroquinolin-4-yl)alkane-1,n-diamine or <i>N</i> -quinolin-4-ylalkane-1,n-diamine
MDR1-MDCK	Kadin Darby canine kidney (MDCK) cells with the MDR1 gene

References

1. Montecucco C, Molgo J. Botulinal neurotoxins: revival of an old killer. *Curr Opin Pharmacol*. 2005; 5:274–279. [PubMed: 15907915]
2. Agarwal R, Swaminathan S. SNAP–25 substrate peptide (residues 180–183) binds to but bypasses cleavage by catalytically active *Clostridium botulinum* neurotoxin E. *J Biol Chem*. 2008; 283:25944–25951. [PubMed: 18658150]
3. Barash JR, Arnon SS. A novel strain of *Clostridium botulinum* that produces type B and type H botulinum toxins. *J Infect Dis*. 2013; 209:183–191. [PubMed: 24106296]
4. Duplantier AJ, Kane CD, Bavari S. Searching for therapeutics against botulinum neurotoxins: a true challenge for drug discovery. *Curr Top Med Chem*. 2016; 16:2330–2349. [PubMed: 27072693]
5. Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: Genetic, structural and mechanistic insights. *Nature Rev Microbiol*. 2014; 12:535–549. [PubMed: 24975322]
6. Pirazzini M, Rossetto O. Challenges in searching for therapeutics against botulinum neurotoxins. *Expert Opin Drug Discov*. 2017; 12:497–510. [PubMed: 28271909]
7. Kiris E, Burnett JC, Nuss JE, Wanner LM, Peyser BD, Du HT, Gomba GY, Kota KP, Panchal RG, Gussio R, Kane CD, Tessarollo L, Bavari S. Src family kinase inhibitors antagonize the toxicity of multiple serotypes of botulinum neurotoxin in human embryonic stem cell-derived motor neurons. *Neurotox Res*. 2015; 27:384–398. [PubMed: 25782580]
8. Pirazzini M, Azarnia TD, Zanetti G, Megighian A, Scorsetto M, Fillo S, Shone CC, Binz T, Rossetto O, Lista F, Montecucco C. Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins. *Cell Rep*. 2014; 8:1870–1878. [PubMed: 25220457]
9. Seki H, Xue S, Pellett S, Šilhár P, Johnson EA, Janda KD. Cellular protection of SNAP 25 against botulinum neurotoxin/A: inhibition of thioredoxin reductase through a suicide substrate mechanism. *J Am Chem Soc*. 2016; 138:5568–5575. [PubMed: 27070533]
10. Kiris E, Nuss JE, Stanford SM, Wanner LM, Cazares L, Maestre MF, Du HT, Gomba GY, Burnett JC, Gussio R, Bottini N, Panchal RG, Kane CD, Tessarollo L, Bavari S. Phosphatase inhibitors function as novel, broad spectrum botulinum neurotoxin antagonists in mouse and human embryonic stem cell-derived motor neuron-based assays. *PLoS ONE*. 2015; 10:e0129264. [PubMed: 26061731]
11. Boldt GE, Kennedy JP, Janda KD. Identification of a potent botulinum neurotoxin A protease inhibitor using in situ lead identification chemistry. *Org Lett*. 2006; 8:1729–1732. [PubMed: 16597152]
12. Burnett JC, Schmidt JJ, Stafford RG, Panchal RG, Nguyen TL, Hermone AR, Vennerstrom JL, McGrath CF, Lane DJ, Sausville EA, Zaharevitz DW, Gussio R, Bavari S. Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. *Biochem Biophys Res Commun*. 2003; 310:84–93. [PubMed: 14511652]
13. Šolaja BA, Opsenica D, Smith KS, Milhous WK, Terzic N, Opsenica I, Burnett JC, Nuss J, Gussio R, Bavari S. Novel 4-aminoquinolines active against chloroquine-resistant and sensitive *P. falciparum* strains that also inhibit botulinum serotype A. *J Med Chem*. 2008; 51:4388–4391. [PubMed: 18637666]
14. Opsenica I, Filipovic V, Nuss JE, Gomba LM, Opsenica D, Burnett JC, Gussio R, Šolaja BA, Bavari S. The synthesis of 2,5-bis(4-amidinophenyl)thiophene derivatives providing submicromolar-range inhibition of the botulinum neurotoxin serotype A metalloprotease. *Eur J Med Chem*. 2012; 53:374–379. [PubMed: 22516424]
15. Burnett JC, Opsenica D, Sriraghavan K, Panchal RG, Ruthel G, Hermone AR, Nguyen TL, Kenny TA, Lane DJ, McGrath CF, Schmidt JJ, Vennerstrom JL, Gussio R, Šolaja BA, Bavari S. A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease. *J Med Chem*. 2007; 50:2127–2136. [PubMed: 17417831]
16. Videnovi M, Opsenica DM, Burnett JC, Gomba L, Nuss JE, Selakovi Ž, Konstantinovi J, Krsti M, Šegan S, Zlatovi M, Sciotti RJ, Bavari S, Šolaja BA. Second generation steroidal 4-aminoquinolines are potent, dual-target inhibitors of the botulinum neurotoxin serotype A

metalloprotease and *P. falciparum* malaria. *J Med Chem*. 2014; 57:4134–4153. [PubMed: 24742203]

17. Pellett S. Progress in cell based assays for botulinum neurotoxin detection. *Curr Top Microbiol Immunol*. 2013; 364:257–285. [PubMed: 23239357]
18. Stahl AM, Ruthel G, Torres-Melendez E, Kenny TA, Panchal RG, Bavari S. Primary cultures of embryonic chicken neurons for sensitive cell-based assay of botulinum neurotoxin: implications for therapeutic discovery. *J Biomol Screen*. 2007; 12:370–377. [PubMed: 17332092]
19. Keller JE, Neale EA, Oyler G, Adler M. Persistence of botulinum neurotoxin action in cultured spinal cord cells. *FEBS Lett*. 1999; 456:137, 142. [PubMed: 10452545]
20. Pellett S, Tepp WH, Clancy CM, Borodic GE, Johnson EA. A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. *FEBS Lett*. 2007; 581:4803–4808. [PubMed: 17889852]
21. Kiris E, Kota KP, Burnett JC, Soloveva V, Kane CD, Bavari S. Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery. *Expert Rev Mol Diagn*. 2014; 14:153–168. [PubMed: 24450833]
22. Bremer PT, Adler M, Phung CH, Singh AK, Janda KD. Newly designed quinolinol inhibitors mitigate the effects of botulinum neurotoxin A in enzymatic, cell-based, and ex vivo assays. *J Med Chem*. 2017; 60:338–348. [PubMed: 27966961]
23. Tehran DA, Zanetti G, Leka O, Lista F, Fillo S, Binz T, Shone CC, Rossetto O, Montecucco C, Paradisi C, Mattarei A, Pirazzini M. A novel inhibitor prevents the peripheral neuromuscular paralysis of botulinum neurotoxins. *Sci Rep*. 2015; 5:17513. [PubMed: 26670952]
24. Eubanks LM, Hixon MS, Jin W, Hong S, Clancy CM, Tepp WH, Baldwin MR, Malizio CJ, Goodnough MC, Barbieri JT, Johnson EA, Boger DL, Dickerson TJ, Janda KD. An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. *PNAS*. 2007; 104:2602–2607. [PubMed: 17293454]
25. Thyagarajan B, Potian JG, Garcia CC, Hognason K, Capkova K, Moe ST, Jacobson AR, Janda KD, McArdle JJ. Effects of hydroxamate metalloendoprotease inhibitors on botulinum neurotoxin A poisoned mouse neuromuscular junctions. *Neuropharmacology*. 2010; 58:1189–1198. [PubMed: 20211192]
26. Pang YP, Davis J, Wang S, Park JG, Nambiar MP, Schmidt JJ, Millard CB. Small molecules showing significant protection of mice against botulinum neurotoxin serotype A. *PloS ONE*. 2010; 5:e10129. [PubMed: 20405003]
27. Eichhorn T, Dolimbek BZ, Deeg K, Efferth T, Atassi MZ. Inhibition in vivo of the activity of botulinum neurotoxin A by small molecules selected by virtual screening. *Toxicon*. 2012; 60:1180–1190. [PubMed: 22960451]
28. Bremer PT, Pellett S, Carolan JP, Tepp WH, Eubanks LM, Allen KN, Johnson EA, Janda KD. Metal ions effectively ablate the action of botulinum neurotoxin A. *J Am Chem Soc*. 2017; 139:7264–7272. [PubMed: 28475321]
29. Jacobson AR, Adler M, Silvaggi NR, Allen KN, Smith GM, Fredenburg RA, Stein RL, Park J-B, Feng X, Shoemaker CB, Deshpande SS, Goodnough MC, Malizio CJ, Johnson EA, Pellett S, Tepp WH, Tzipori S. Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A. *Toxicon*. 2017; 137:36–47. [PubMed: 28698055]
30. Seki H, Xue S, Hixon MS, Pellet S, Remes M, Johnson EA, Janda KD. Toward the discovery of dual inhibitors of botulinum neurotoxin A: concomitant targeting of endocytosis and light chain protease activity. *Chem Commun*. 2015; 51:6226–6229.
31. Konstantinovi J, Videnovi M, Srbljanovi J, Djurkovi -Djakovi O, Bogojevi K, Sciotti R, Šolaja B. Antimalarials with benzothioephene moieties as aminoquinoline partners. *Molecules*. 2017; 22:343.
32. Terzi N, Konstantinovi J, Tot M, Burojevi J, Djurkovi -Djakovi O, Srbljanovi J, Štajner T, Verbi T, Zlatovi M, Machado M, Albuquerque IS, Prudêncio M, Sciotti RJ, Pecic S, D'Alessandro S, Taramelli D, Šolaja BA. Reinvestigating old pharmacophores: are 4-aminoquinolines and tetraoxanes potential two-stage antimalarials? *J Med Chem*. 2016; 59:264–281. [PubMed: 26640981]

33. Markovi OS, Cvijeti IN, Zlatovi MV, Opsenica IM, Konstantinovi JM, Terzi Jovanovi NV, Šolaja BA, Verbi TŽ. Human serum albumin binding of certain antimalarials. *Spectrochim Acta Mol Biomol Spectrosc*. 2018; 192:128–139.
34. Aleksi I, Šegan S, Andri F, Zlatovi M, Moric I, Opsenica DM, Senerovic L. Long-chain 4-aminoquinolines as quorum sensing inhibitors in *Serratia marcescens* and *Pseudomonas aeruginosa*. *ACS Chem Biol*. 2017; 12:1425–1434. [PubMed: 28350449]
35. Nuss JE, Wanner LM, Tressler LE, Bavari S. The osmolyte trimethylamine N-oxide (TMAO) increases the proteolytic activity of botulinum neurotoxin light chains A, B, and E: implications for enhancing analytical assay sensitivity. *J Biomol Screen*. 2010; 15:928–936. [PubMed: 20720092]
36. Sobanska AW, Wójcicka K, Brzezinska E. Evaluation of the lipophilicity of selected sunscreens – a chemometric analysis of thin-layer chromatographic retention data. *J Sep Sci*. 2014; 37:3074–3081. [PubMed: 25146246]
37. Takács-Novák K, Avdeel A. Interlaboratory study of log*P* determination by shake-flask and potentiometric methods. *J Pharm Biomed Anal*. 1996; 14:1405–1413. [PubMed: 8877846]
38. EPA 712-C-96-038, *Product Properties Test Guidelines, OPPTS 830.7550: Partition coefficient (n-octanol/water), shake flask method*. U.S. Environmental Protection Agency; Washington D.C.: 1996.
39. Test No. 107: Partition Coefficient (n-octanol/water): Shake Flask Method. OECD; Paris: 1995. OECD Guidelines for the testing of chemicals, Section 1. Physical-chemical properties. <http://dx.doi.org/10.1787/9789264069626-en>. Assessed 15 January 2018
40. Department of Defense, ADMET Center at USAMRICD, Gunpowder, Maryland, USA.
41. Di L, Kerns EH. Profiling drug-like properties in discovery research. *Curr Opin Chem Biol*. 2003; 7:402–408. [PubMed: 12826129]
42. Yamasaki K, Chuang VTG, Maruyama T, Otagiri M. Albumin-drug interaction and its clinical implication. *Biochim Biophys Acta*. 2013; 1830:5435–5443.
43. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. *Drug Metab Rev*. 2001; 33:161–235. [PubMed: 11495502]
44. Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. *Nat Rev Drug Discov*. 2010; 9:929–939. [PubMed: 21119731]
45. Ruthel G, Burnett JC, Nuss JE, Wanner LM, Tressler LE, Torres-Melendez E, Sandwick SJ, Retterer CJ, Bavari S. Post-intoxication inhibition of botulinum neurotoxin serotype A within neurons by small-molecule, non-peptidic inhibitors. *Toxins*. 2011; 3:207–217. [PubMed: 22069707]
46. Kim S, Oh CH, Ko JS, Ahn KH, Kim YJ. Zinc-modified cyanoborohydride as a selective reducing agent. *J Org Chem*. 1985; 50:1927–1932.
47. Amoroso F, Colussi S, Del Zotto A, Llorca Piqué J, Trovarelli A. PdO hydrate as an efficient and recyclable catalyst for the Suzuki-Miyaura reaction in water/ethanol at room temperature. *Cat Commun*. 2011; 12:563–567.
48. Musonda CC, Gut J, Rosenthal PJ, Yardley V, Carvalho de Souza RC, Chibale K. Application of multicomponent reactions to antimalarial drug discovery. Part 2: New antiplasmodial and antitrypanosomal 4-aminoquinoline γ and δ -lactams via a ‘catch and release’ protocol. *Bioorg Med Chem*. 2006; 14:5605–5615. [PubMed: 16690319]
49. Peck RM, Preston RK, Creech HJ. Nitrogen mustard analogs of antimalarial drugs. *J Am Chem Soc*. 1959; 81:3984–3989.
50. Price CC, Leonard NJ, Peel EW, Reitsema RH. Some 4-amino-7-chloroquinoline derivatives. *J Am Chem Soc*. 1946; 68:1807–1808. [PubMed: 21001098]
51. Singh C, Malik H, Puri SK. Synthesis and antimalarial activity of a new series of trioxaquinones. *Bioorg Med Chem*. 2004; 12:1177–1182. [PubMed: 14980628]
52. Kiris E, Nuss JE, Burnett JC, Kota KP, Koh DC, Wanner LM, Torres-Melendez E, Gussio R, Tessarollo L, Bavari S. Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery. *Stem Cell Res*. 2011; 6:195–205. [PubMed: 21353660]

53. Wichterle H, Lieberam I, Porter JA, Jessell TM. Directed differentiation of embryonic stem cells into motor neurons. *Cell*. 2002; 110:385–397. [PubMed: 12176325]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1. Protection of SNAP-25 in mES-MNs in pre-intoxication model (results are given as mean value of three independent experiments $\pm$ SEM, values given in Table S2).

Figure 2. Protection of SNAP-25 in mES-MNs in post-intoxication model at 20 μ M (results are given as mean value of three independent experiments $\pm$ SEM, values given in Table S3).

Figure 3.

Protection of SNAP-25 in mES-MNs by compounds **16** and **24** administered 30 min post-intoxication – dose response experiment 0.25 to 64 μM (results are given as mean value of two independent experiments $\pm$ SEM, values given in Table S4). $\text{IC}_{50} \sim 8 \mu\text{M}$. Compound **16** showed potential toxicity at 64 μM , since GAPDH (used as loading control) levels were lower. In the independent dose-response experiment, **16** showed protection of SNAP-25 up to 64% at 20 μM (Figure S2, values given in Table S6).

Figure 4. Pharmacokinetics of **16** in mice serum after oral dosing at two concentrations – 400 and 600 mg/kg.

Scheme 1.
 Synthesis of novel steroidal derivatives **14-24**

i) $(\text{NH}_4)_2\text{CO}_3$, phenol, 110 to 165 °C, 3.5 h; ii) 4-chlorobutanoyl chloride, Et_3N , CH_2Cl_2 , 0 °C to r.t.; iii) NaN_3 , DMF, 80 °C; iv) Ph_3P , THF, H_2O , 65 °C; v) 1) aldehyde, dry MeOH, 2) NaBH_4 ; vi) CF_3COOH , CH_2Cl_2

Scheme 2.
Synthesis of steroidal derivative **30**

i) 1) aminoquinoline/aldehyde, AcOH glaci, MeOH/CH₂Cl₂, rt, 2 h 2) NaBH₄, rt, 12 h; ii) HCHO, MeOH, ZnCl₂, NaBH₃CN; iii) K₂CO₃, MeOH, rt

Scheme 3.

Synthesis of novel benzothiophene (33, 34, 37, 38) and thiophene (42-44, 47, 48, 50) derivatives

i) 1) aminoquinoline/aldehyde, AcOH glaci, MeOH/CH₂Cl₂, rt, 2 h 2) NaBH₄, rt, 12 h; ii) HCHO, MeOH, ZnCl₂, NaBH₃CN; iii) aldehyde, NaBH(OAc)₃, CH₂Cl₂, rt, 24 h; iv) 4-chloroquinoline, Pd(OAc)₂, SPhos, K₃PO₄, dioxane, 85 °C, 24 h

Scheme 4.

Synthesis of novel adamantane derivatives **56-69**, **77-82**, **84** and **85**

Chart 1.
General structures of investigated steroidal, benzothiophene, thiophene and adamantane derivatives

Table 1Inhibitory activities against BoNT/A LC and holotoxin in proteolytic and cell-based assay^a

Compound ^b	exp LogD ^c	In vitro proteolytic assay % inh BoNT/A LC at 20 μM; IC ₅₀ (μM)	mES-MNs pre intoxication % of full length SNAP-25 (10μM; 20μM)	mES-MNs post intoxication at 20 μM % of full length SNAP-25 (30 min; 60 min)
14	2.14 (pH=1)	80; 5.7	28; 67	48; 49
15	2.11 (pH=1)	52; 1.5	70; 69	–
16	2.55 (pH=1); 2.07 (pH=7.3) ^d	66; 4.5	72; 88	64; 45
17	2.28 (pH=1)	71; 2.7	67; 69	38; 22
18	2.38 (pH=1)	85; 0.7	20; 41	–
19	2.21 (pH=1)	75; 3.0	86; 87	50; 22
24	2.97 (pH=1)	48	46; 58 ^e	49; ^e –
34	3.85 (pH=10)	75; 7.4	58; 68	16; 17
36	3.67 (pH=10)	61; 10.2	34; 53	–
37	3.98 (pH=10)	46	44; 55	–
38	3.42 (pH=10)	27	59; 64	–
86	3.67 (pH=10)	84; 4.6	21; 26	–
87	3.85 (pH=10)	75; 3.3	36; 43	–
91	3.98 (pH=10)	69; 8.8	62; 62	–
46	3.08 (pH=1)	70–80; 3.4	22; 48	–
50	3.08 (pH=1)	68; 8.7	46; 71	–
93	3.42 (pH=1)	77; 6.8	31; 70	20; 19
96	3.33 (pH=1)	35	54; 60	34; 22
101	2.93 (pH=1)	67; 9.3	18; 39	–
57	3.24 (pH=10)	71; 8.8	51; 56	46; 39
60	3.47 (pH=10)	67; 11.7	63; 72	15; 16
68	–	30	30; 31	–
81	–	–	23; 24	–
85	–	51; 5.2	47; 46	–
102	3.40 (pH=10)	65; 2.7	29; 30	–
103	4.33 (pH=10)	2	30; 29	–
104	3.24 (pH=10)	15	31; 35	–
105	3.09 (pH=10)	–	24; 23	–
106	4.13 (pH=10)	–	30; 32	–
Negative control DMSO	–	–	100	100
Positive control 1	–	90; 12.4 ^f	70; 84	36; 20

^aResults are given as mean value of three independent experiments.^bSyntheses of compounds **36**, **46**, **86**, **87**, **91**, **93**, **96** and **101** were reported in our previous work.³¹ Syntheses of compounds **102–106** were reported in our previous work.³²

^cExperimental Log*D* using reversed phase thin-layer chromatography at pH=1 (MeOH/HCl (70/30)) or pH=10 (acetone/NH₃/H₂O (85/5/10)).

^dExperimental Log*D* in octanol/TBS buffer at pH=7.3 using shake flask method.

^eCompound **24** was tested at 8 and 16 μM in pre-intoxication model and at 16 μM in 30 minutes post-intoxication model only;

^fIn previous test the inhibition was 95.46% and $K_i = 0.285\text{OM}$.¹⁶

Table 2Toxicity study in mice^a

Compound (at 3 × 160 mg/kg dose)	Mice alive/Total mice
16	5/5
19	3/5
34	5/5
57	4/5
60	3/5
93	5/5
96	5/5

^aGroups of five healthy mice were treated per os (p.o.) for three consecutive days with aminoquinolines suspended in 0.5% hydroxyethylcellulose –0.1% Tween 80. Individual mouse behavior and appearance was monitored two times a day for 30 days.

Table 3ADMET parameters for compound **16**⁴⁰

ADMET Properties		
Purity of the sample (%) ^a		>90
Solubility at pH 7.4 (µg/mL) ^b		>50
Stability – Microsomes ^c	<i>T</i> _{1/2} (min)	>60
	CL _{int} (µL/min/mg)	<23
Stability - Human plasma (% remaining at 1 h) ^d		>85
CYP450 Inhibition IC ₅₀ (µM) ^{e,f}		1–10
MDRI-MDCK ^g	P _{app} (a–b, 10 ^{–6} cm/s)	45.3
	Pgp Efflux Ratio	0.54
Plasma protein binding (%) ^h		>99

^aPurity analysis was determined by LC-MS/MS.^bSolubility (*n*=3) was determined using laser nephelometry to measure light scattering.^cSubstrate depletion experiments were performed by incubating test compound with liver microsomes (human and mouse) for 1 hour at 37°C.^dPlasma stability was determined following incubation for 1 hour at 37°C.^eThe IC₅₀ value was determined from the net fluorescent signal from incubation at 37°C for a set time with an active cytochrome P450 enzyme and a fluorescent probe substrate.^fFor CYP3A4/BQ (1.1 µM), CYP3A4/DBF (1.2 µM), CYP3A4/BFC (1.4 µM), CYP2C19/CEC (5 µM) and CYP2D6/AMMC (>10 µM).^gThe MDR1/MDCK apparent permeability constant (P_{app}) was determined after 1 hour incubation at 37 °C of the compound on the apical compartment (A to B) or basolateral compartment of the cell monolayer (B to A). The Efflux Ratio is the ratio of the P_{app} in the B to A direction divided by the P_{app} in the A to B direction.^hAccording to equilibrium dialysis method.

Table 4

Concentration levels of **16** in mouse serum at different time points following oral administration at two different doses.^a

Time (min)	400 mg/kg dose µg/mL (µM)	600 mg/kg dose µg/mL (µM)
15	2.3 (3.3)	8.5 (11.9)
22	5.5 (7.8)	<i>_b</i>
30	2.8 (4.0)	4.2 (5.9)
45	2.3 (3.3)	2.2 (3.1)
60	2.0 (2.8)	<LOQ ^c
90	<LOD	2.8 (4.0)
120	<LOD	<LOQ ^d

^aConcentration µg/mL of compound was determined by UPLC-MS/MS. Concentration in µM is given in parentheses. Results are given as a single value for one mouse for each time point. LOD = limit of detection; LOQ = Limit of quantitation.

^bSample was not taken.

^cConcentration was estimated to 1.8 µg/mL (2.5µM)<LOQ.

^dConcentration was estimated to 1.7 µg/mL (2.4µM)<LOQ.

Table 5

In vivo pharmacokinetic properties for **16** in mice after oral administration at two different concentrations

parameter	400 mg/kg dose	600 mg/kg dose
$T_{\max}$ (min)	22	15
$C_{\max}$ (μM)	7.8	11.9
AUC_{0-120} ($\mu\text{M}\cdot\text{min}$)	253	526
$t_{1/2}$ (min) ^a	43	23
time $T_{c>3\mu\text{M}}$ (min)	>45	>45
Plasma protein binding (%) ^b	>99%	>99%

^a $t_{1/2}$ (min) values calculated from graph on Fig. 4 using GraphPad Prism 6;

^b According to no detection of free concentration (ultracentrifugation method, see Materials and Methods)